Mycophenolate Mofeti

PreclinicalSmall molecule

Mycophenolate Mofeti is one of 5 small molecule programs targeting Peripheral Blood Stem Cell Transplantation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral Blood Stem Cell TransplantationRecruiting

Peripheral Blood Stem Cell TransplantationPreclinical

Recruiting

Competition

Competitive Landscape

5 competitors in Peripheral Blood Stem Cell Transplantation

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Phase 3

2 2

Prograf

VVeloxis Pharmaceuticals

Phase 3

3 3

Velcade

SShilpa Grover, MD, MPH

Phase 2

2 4

Darzalex

Qilu Pharmaceutical Co., Ltd.

Phase 1

1 5

Mycophenolate Mofeti

NNational Cancer Institute (NCI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Peripheral Blood Stem Cell Transplantation

NCT05436418

Clinical

Trials by Indication[1]

Peripheral Blood Stem Cell Transplantation1 trial

Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT05436418·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mycophenolate Mofeti. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mycophenolate Mofeti compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mycophenolate Mofeti. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Cancer Institute (NCI)

Mycophenolate Mofeti

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Peripheral Blood Stem Cell Transplantation1 trial

References

Drug Info

Quick Facts

Related News